Tuberculosis (TB) and cirrhosis of the liver are both endemic in many regions of the world. However, the risk of TB in cirrhotic patients has rarely been investigated. A nationwide cohort study was conducted to elucidate and characterize the association between cirrhosis and TB in Taiwan. The study included 41,076 cirrhotic patients and 204,244 noncirrhotic controls from 1998 through 2007. Cirrhotic and noncirrhotic subjects were matched 1:5 on age and sex. A total of 957 of 41,076 (2.32%) cirrhotic patients developed TB, yielding a rate that was significantly higher than that of the 955 of 204,244 (0.46%) noncirrhotic patients (P < 0.001). In a Cox regression model adjusted for age, sex, and underlying medical disorders, a significantly higher active TB rate was maintained for cirrhotic patients compared with their noncirrhotic counterparts (adjusted hazard ratio = 3.55, 95% confidence interval (CI): 3.08, 4.09; P < 0.001). Alcoholism and hepatitis C infection were associated with significantly higher TB risk with adjust hazard ratios of 2.18 (95% CI: 1.86, 4.09; P < 0.001) and 1.18 (95% CI: 1.02, 1.30; P < 0.001), respectively. Cirrhotic patients have a greater risk of TB than noncirrhotic patients, particularly those with alcoholism and hepatitis C infection.
Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, is a major health problem and remains the leading cause of death from infectious disease worldwide (1, 2) . It is estimated that one-third of the global population harbors TB in its latent form. With aging or a weakened immune system, the causative TB microorganism can reactivate and cause severe and prolonged pneumonia, pulmonary scarring, and wasting. Without treatment, TB causes chronic inflammation and is associated with a mortality rate of 50% within 5 years (3). There is an incrementally increasing trend of newly infected cases and deaths globally, although standard anti-TB treatment has been highly effective in the past decades. Nonadherence to treatment and subtle disease progression, particularly in immune-compromised patients, remain the major obstacles to successful treatment and control (4) .
Apart from age, male sex, malnutrition, low socioeconomic status, and substance abuse, the risk of TB is often attributed to impaired host immunity (5, 6) . Diabetes mellitus (DM), chronic renal failure (CRF), chronic obstructive pulmonary disease (COPD), silicosis, cancer, human immunodeficiency virus infection, being a transplantation recipient, and the use of glucocorticoids have been postulated to be host factors for TB (1, 2, (7) (8) (9) (10) (11) (12) (13) . Generally, patients with cirrhosis show acquired immune dysfunction because of poor homeostasis and malnutrition. Most of the host defense systems are compromised in cirrhotic patients, including antigen-presenting functions, clearance capacities of the reticuloendothelial system, and leukocyte functions (14) . However, the impact of cirrhosis, the leading cause of death and liver transplantation worldwide, on the risk of TB has rarely been investigated (15, 16) .
In Taiwan, TB remains a major public health problem, with a population incidence of 74.6 cases per 100,000 (17) . Meanwhile, end-stage liver disease and hepatocellular carcinoma, which are subsequent complications of both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, represent a tremendous health burden in Taiwan. The prevalence of HBV infection is 15%-20% in the general population, and the prevalence of HCV infection reaches 8.6% in southern Taiwan (18) . The unique situation in this developed country thus provides an excellent backdrop for addressing the risk of TB in cirrhotic patients. We hypothesized that cirrhosis is a predisposing factor for active TB. The study aimed to determine the association between cirrhosis and active TB by analyzing a nationwide cohort database derived from the public health insurance system in Taiwan.
METHODS

Data source
This study is based on a longitudinal health insurance database, the National Health Insurance Research Database (NHIRD), provided by the Taiwan National Health Research Institute. Taiwan has launched a compulsory social insurance program, the National Health Insurance program, which has provided health care for all residents since 1995. The annual coverage rate of the National Health Insurance program ranges from 96.2% to 99.6% with more than 23 million Taiwanese residents enrolled. More than 97% of hospitals and clinics nationwide have been included since 1997. It covers all medical care claims and is used extensively for epidemiologic studies. The NHIRD established a registry system for "catastrophic illnesses," including cancers, cirrhosis, end-stage renal disease, congenital illness, and several autoimmune diseases. Insured persons with these major diseases can apply for catastrophic illness registration cards from the Bureau of National Health Insurance, Taiwan. Both outpatient and inpatient claims of beneficiaries with a catastrophic illness certificate are registered in the Catastrophic Illness Database. The Bureau of National Health Insurance routinely performs validation of the diagnoses by reviewing the original medical charts of all patients who apply for catastrophic illness registration. In this study, data on all cases of cirrhosis were obtained from the Registry of Catastrophic Illness Database, a subpart of the NHIRD. Furthermore, the issuance of catastrophic illness certificates for cirrhosis is validated by gastroenterologists through examination of medical records and laboratory and imaging studies. Consequently, the cirrhosis diagnoses and coding in the Catastrophic Illness Database are quite accurate. The database includes all relevant information about the catastrophic illness certificate status, such as International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, date of diagnosis, date of death, dates of every clinic visit, details of prescriptions, expenditure amounts, and outpatient and inpatient claim data for the beneficiaries with catastrophic illnesses. This study was approved by the ethical review board of the National Health Research Institutes, Taiwan.
Study cohorts
The definition of cirrhosis required the ICD-9-CM code 571.2, 571.5, or 571.6, as well as certification in the Registry of Catastrophic Illness Database between January 1, 1998, and December 31, 2007 . The index date of cirrhosis was defined on the basis of claims from hospitalization or 2 consecutive outpatient clinic visits. Individuals younger than 20 years were excluded (n = 121). Patients with incomplete or missing basic data (n = 53) or TB diagnosis before the index date (n = 197) were also excluded. Cirrhotic and noncirrhotic patients were age, sex-, and index date-matched at a 1:5 ratio. The database contains all medical claims data for 1 million beneficiaries randomly sampled from the registry of the NHIRD with no statistically significant differences in age, sex, or health care costs between the sample group and the original registered population. The cirrhotic cohort and noncirrhotic cohort were both enrolled between January 1, 1998, and December 31, 2007, and were followed up until the diagnosis of TB or the end of 2008 ( Figure 1 ).
Definition of TB and comorbidities
TB was defined by using ICD-9-CM codes for TB (codes 010-018) with at least 2 ambulatory visits or hospitalizations for a major diagnosis. It was further confirmed on the basis of the medical records indicating simultaneous prescriptions for 2 or more anti-TB drugs for more than 60 days during a 180-day period. The anti-TB drugs included isoniazid, ethambutol, rifampin, pyrazinamide, prothionamide, cycloserine, aminoglycosides (streptomycin, amikacin, and kanamycin), and quinolone (levofloxacin and moxifloxacin). In Taiwan, TB is a notifiable infectious disease. When an incident TB patient is diagnosed and anti-TB drugs are prescribed, an official notification to the Taiwan Center for Disease Control must be performed by medical professionals within 1 week. We defined a TB-positive patient as one who was diagnosed and who took anti-TB drugs for more than 60 days because, generally, it takes 2 months for the validation of a TB culture. The comorbidities identified in this study were DM (ICD-9-CM code 250), CRF (ICD-9-CM code 585), autoimmune disease (ICD-9-CM codes 710 and 714), COPD (ICD-9-CM codes 491, 492, and 496), silicosis (ICD-9-CM codes 501-504), cancer (ICD-9-CM codes 140-208), human immunodeficiency virus infection (ICD-9-CM code 042), organ transplantation (ICD-9-CM codes 996 and V042), HBV (ICD-9-CM codes 070.2, 070.3, and V02.61), and HCV (ICD-9-CM codes 070.7, 070.41, 070.44, 070.51, 070.54, and V02.62). The comorbidities were coded during at least 2 ambulatory visits or 1 hospitalization. Alcoholism was also defined according to ICD-9 codes (Web Table 1 available at http://aje.oxfordjournals.org/).
Sensitivity analyses
We performed sensitivity analyses to assess the robustness of the main findings with different assumptions. These included the following: 1) inclusion of cirrhotic subjects with HBV infection only; 2) inclusion of cirrhotic patients with HCV infection only; 3) inclusion of cirrhotic patients with alcoholism only; 4) inclusion of nondiabetic subjects only; 5) inclusion of subjects without a history of DM, alcoholism, or HCV infection; and 6) inclusion of subjects without a history of DM, CRF, autoimmune disease, COPD, cancer, or alcoholism.
Statistical analysis
Normally distributed continuous data are expressed as means and standard deviations. Numerical data with nonnormal distributions are expressed as medians and interquartile ranges. The Student's t test was used for parametric continuous data between groups, and the χ 2 test was used for categorical data. The differences between groups during the follow-up period were analyzed using the Kaplan-Meier method with a log-rank test. We used the Cox proportional hazards model assumption test with trend tests of the Schoenfeld residuals. This included a time-varying covariate to test the interaction between the predictors and the event time. There was no significant interaction between the predictors and the event time, indicating that the assumption was fulfilled (P = 0.15). In addition, multivariate Cox proportional hazards regression was performed with forward elimination to analyze independent risk factors for TB. Death occurring prior to active TB infection was considered a competing risk event in analysis. We also applied a modified Cox proportional hazards model in the presence of a competing risk event to examine the independent association between cirrhosis and active TB (19) . The influence of cirrhosis on TB was further explored in different strata according to age, sex, and comorbidity status. The hazard ratios were determined along with the 95% confidence intervals. Statistical significance was inferred on the basis of a 2-sided P value of less than 0.05. Analyses were performed using SAS, version 9.2, software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Risk of TB for cirrhotic patients and controls
Patients' characteristics and selected comorbid medical disorders at baseline are presented in Table 1 . There were 41,076 cirrhotic patients with a mean age of 52.9 (standard deviation, 13.8) years who were compared with 204,244 matched noncirrhotic controls. During the follow-up period, TB was diagnosed in 957 cirrhotic patients (2.32%), corresponding to an Table 2 ). The active pulmonary and extrapulmonary TB incidence rates among cirrhotic patients were significantly higher than those among noncirrhotic patients ( Table 2 ). The active TB risk of the cirrhotic patients was significantly higher than that of the noncirrhotic patients (P < 0.001) with an incidence rate ratio of 7.84 (95% CI: 7.17, 8.57). The cumulative incidence rates of TB were higher in cirrhotic patients than in their matched controls (P < 0.001) when using the KaplanMeier approach (Figure 2 ). We performed a Cox regression analysis with a forward selection procedure based on the likelihood ratio (Table 3 ). The hazard ratio for TB in cirrhotic patients was 3.55 (95% CI: 3.08, 4.09; P < 0.001) after adjustment for age, sex, living area, socioeconomic status, DM, CRF, autoimmune disease, COPD, silicosis, cancer, HBV infection, HCV infection, and alcoholism. After further accounting for death as the competing cause of risk and adjusting for multiple confounding factors, we found that cirrhosis remained significantly associated with active TB with an adjusted hazard ratio of 2.83 (95% CI: 2.45, 3.28; P < 0.001).
There was no significant difference between TB incidence in cirrhotic patients with alcoholism (565 per 100,000 person-years, 95% CI: 521.6, 610.6) and those without alcoholism (281 per 100,000 person-years, 95% CI: 251.8, 311.6).
Other factors contributing to TB
Multivariate analysis demonstrated that alcoholism was the leading risk for TB (hazard ratio (HR) = 3.17, 95% CI: 2.78, 3.61; P < 0.001), followed by silicosis (HR = 2.63, 95% CI: 1.25, 5.53; P = 0.011), male sex (HR = 2.01, 95% CI: 1.78, 2.26; P < 0.001), COPD (HR = 1.58, 95% CI: 1.40, 1.78; P < 0.001), CRF (HR = 1.51, 95% CI: 1.19, 1.92; P < 0.001), DM (HR = 1.39, 95% CI: 1.24, 1.56; P < 0.001), geographical area (HR = 1.20, 95% CI: 1.09, 1.32; P < 0.001), and HCV infection (HR = 1.17, 95% CI: 1.02, 1.34; P = 0.027) ( Table 3) .
Cirrhosis associated with TB in other risk groups
The multivariate stratified analysis demonstrated that cirrhosis was associated with the risk of TB in all subgroups (Figure 3) . In cirrhotic patients, male sex, DM, CRF, COPD, and silicosis were associated with TB infection. In contrast, cirrhosis was not associated with higher risk of TB among patients with autoimmune disease and cancer. Among the etiological bases of cirrhosis, alcoholism and HCV infection were associated with significantly higher TB risk with adjusted hazard ratios of 2.18 (95% CI: 1.86, 4.09; P < 0.001) and 1.18 (95% CI: 1.02, 1.30; P < 0.001), respectively. HBV infection was not associated with higher TB risk in cirrhotic patients (Table 4 ).
Sensitivity analyses
We tested the robustness of our study with a series of sensitivity analyses. The results regarding the association of cirrhosis with TB were consistent among the various subgroups. In all of these analyses based on different assumptions, cirrhotic patients had a significantly higher risk of active TB compared with noncirrhotic patients (Web Table 2 ). 
DISCUSSION
The impact of cirrhosis on the risk of active TB and the characteristics of the relationship have not been well established. To the best of our knowledge, this is the first study to investigate the issues by adjusting for comorbidities in a large-scale longitudinal cohort. We demonstrated that the active TB risk in cirrhotic patients was significantly higher than in noncirrhotic patients. The current study showed that, in addition to cirrhosis, age, sex, DM, CRF, COPD, silicosis, and alcoholism were also independent risk factors. We also demonstrated that HCV infection, but not HBV infection, was associated with a higher risk of active TB in cirrhotic patients.
Various cytokines and cell types are essential in the control of TB. T cells (CD4+, CD8+, and natural killer T cells) and macrophages participate in protection against TB, and γ interferon and tumor necrosis factor α are crucial cytokines for the control of acute TB infection (20) (21) (22) . Cirrhosis, which is associated with lymphocyte and macrophage dysfunction and decreased production of γ interferon and tumor necrosis factor α, may be linked to a higher TB risk (14) .
The liver contains 90% of the cells of the reticuloendothelial system (namely, Kupffer cells and sinusoidal endothelial cells), which are essential for bacteria eradication. Monocyte spread, chemotaxis, bacterial phagocytosis, and bacterial killing are significantly deteriorated in cirrhosis (23) . In addition to reticuloendothelial system dysfunction, patients with cirrhosis have decreased neutrophil mobilization and phagocytic activity, which is a phenomenon that correlates with the severity of liver disease (24) . The decreased phagocytic activity and the characteristic neutropenia, hyperammonemia, and hyponatremia are exacerbated by shortened neutrophil survival and decreased bactericidal and opsonization capacity (25) (26) (27) .
Over the past decade, Taiwan has initiated numerous programs for the prevention of TB, and the incidence rate of TB in Taiwan has gradually declined. Nonetheless, TB remains a lethal infectious disease in Taiwan. The diagnosis of active TB is based on clinical suspicion followed by chest radiography and confirmation by smear and culture. Combined treatment after definite diagnosis is used for active TB in Taiwan, in accordance with current international guidelines (28) . We identified TB cases on the basis of both the ICD-9-CM codes 010-018 and a history of prescriptions for anti-TB medication. Our cirrhotic patients were recruited upon their acquisition of a catastrophic illness certificate, which implied an advanced stage of cirrhosis. Our stringent definitions of active TB and cirrhosis strengthen the link we found between cirrhosis and the risk of active TB. Cirrhotic patients are particularly vulnerable to TB, because their condition generally contraindicates isoniazid prophylaxis. Thus, it is important to investigate whether cirrhosis is a risk factor for TB. Moreover, TB treatment is challenging in cirrhotic patients because of potential hepatotoxicity of standard therapy. Therefore, early diagnosis of TB in cirrhotic patients is warranted. Our results imply that primary health care providers should pay close attention to cirrhotic patients with a chronic cough, fever, or other manifestation of active TB.
The majority of cirrhotic patients with TB will develop advanced-stage liver disease. In a Danish cohort of TB patients with cirrhosis, the TB incidence rate in cirrhotic patients was higher than in the general population (168.6 per 100,000 person-years vs. 7.8 per 100,000 person-years), and the highest incidence rate, 246 per 100,000 person-years of risk, was among men over 65 years of age (16) . However, the results were strongly undermined by lack of adjustment for other TB-associated comorbidities. Observations from other similar studies were limited by small numbers of patients or by lack of adjustment for alcoholism and other clinical manifestations (29, 30) . After adjustment for the presence of alcoholism, the current study demonstrated that alcoholism remains a major risk for active TB in cirrhotic patients. The precise pathogenic mechanisms underlying how alcoholism might exacerbate TB risk are not clear. Chronic and acute alcohol consumption is associated with a decrease in T-cell, B-cell, natural killer cell, and monocyte functions. An immune-compromised state of alcoholism, particularly in cirrhosis, may play a major role in this observation (31) . Intriguingly, our study demonstrated in subgroup analysis that HCV infection, but not HBV infection, is a risk factor for TB in cirrhotic patients. HCV has been shown to be a lymphotropic, as well as a hepatotropic, virus. HCV may induce an immune response mediated by Th1 lymphocytes, leading to activation of the tumor necrosis factor α system, elevation of the interleukin-6 level, reduced interleukin-2 production by CD4+ T cells, and dysfunction of CD8+ T cells (32) . Apart from multiple extrahepatic manifestations of HCV infection, the risk of TB might be listed as a potential extrahepatic complication, particularly in cirrhotic patients. Nonetheless, the varied impact of active TB risk between different viral etiologies should be further evaluated. Besides, interferon α was used to treat HCV infection more frequently than to treat HBV infection, which may be associated with TB.
The current study has some limitations. First, this is a retrospective cohort study based on diagnostic codes and prescription histories. We did not use the standard procedure for diagnosis of active TB (i.e., acid-fast stain and culturing). Instead, we diagnosed active TB if a patient received anti-TB medication for more than 60 days. It is likely that some patients with active TB did not receive medication or died before 2 months of treatment. Nonetheless, the reported TB incidence rate was 65 per 100,000 person-years, which is comparable to data from the Taiwan Center of Disease Control (8) . Second, latent TB could not be evaluated in the present study because tuberculin skin tests and interferon γ release assay testing were not routinely used in patients in our NHIRD database. Therefore, the exact rates of latent TB between cirrhotic and noncirrhotic patients in the present study were not available. However, the tuberculin skin test is reliable for diagnosing latent TB infection because neonatal Bacillus Calmette-Guérin vaccination has been part of the national immunization program in Taiwan since 1965. Further elucidation of the impact of cirrhosis of different etiologies on latent TB will help clarify this issue. Third, our data notably lacked information on the severity of cirrhosis based on the Child-Pugh classification score or the model for end-stage liver disease. A further longitudinal hospital-based cohort will be needed to clarify whether the incidence of active TB is correlated with disease severity of cirrhosis. Finally, our database did not include complete individual-level information such as smoking, nutritional status, intravenous drug abuse, occupational exposure, and contact history of TB, all of which may contribute to active TB. Therefore, to prevent potential bias in our findings, we selected and adjusted for related major and common medical comorbidities, such as alcoholism and autoimmune disease. In summary, our findings provide solid epidemiologic evidence that cirrhotic patients are at a greater risk for active TB, especially in the presence of alcoholism or HCV infection. Primary health care providers should be aware of the risk of active TB in cirrhotic patients.
